Dechra Pharmaceuticals PLC (LON:DPH) said the stronger than expected trading performance has continued to the end of its financial year on 30 June.
The vet products developer said it delivered “excellent” year-on-year organic revenue growth helped by the product acquisitions of Osurnia and Mirataz.
Revenue in the period climbed 18%, with Europe up 20% and North America up 14%.
Mirataz launched in Europe and globally performing ahead of expectations.
Management noted that it’s not “yet fully clear” what is driving this strong growth although broker Liberum said it’s “likely a combination of greater companion animal volumes aided by increased spend per pet as owners have been more cognitive of their pet’s welfare during lockdowns”.
Shares were flat at 4,590p on Monday morning.